东诚药业：氟[18F]思睿肽注射液上市申请获受理 目前国内未有同类产品上市

Core Viewpoint - Dongcheng Pharmaceutical (002675.SZ) has received a notice from the National Medical Products Administration regarding the acceptance of its application for the marketing authorization of Fluorine-18 PSMA peptide injection, a targeted radioactive diagnostic drug for prostate cancer patients [2] Group 1: Product Development - The drug is designed for PET imaging in prostate cancer patients and is the first of its kind to be approved for marketing in China, with similar products already available and performing well in international markets [2] - The company acknowledges the inherent uncertainties in new drug development and commits to actively advancing the subsequent processes while ensuring timely information disclosure [2]